Former RadNet CTO joins Neurophet as scientific advisor
The neuroradiologist and former RadNet CTO will advise the neuroimaging AI company as it seeks to strengthen clinical validation and U.S. market expansion.
Neurophet has appointed neuroradiologist Lawrence N. Tanenbaum, MD, FACR, as scientific advisor. The company said the appointment is intended to support clinical validation, global expansion, and neuroimaging AI competitiveness.
Tanenbaum has more than 30 years of experience across clinical practice, academic research, healthcare technology, and imaging AI. He most recently served as vice president and chief technology officer at RadNet, where he led imaging technology strategy and AI integration across the company’s national imaging network, according to Neurophet.
Before RadNet, Tanenbaum was director of MRI, CT, and advanced imaging and associate professor of radiology at the Icahn School of Medicine at Mount Sinai in New York. He is also a fellow of the American College of Radiology and has served on the Roster of Distinguished Scientific Advisors of RSNA.
Neurophet said Tanenbaum has held advisory and leadership roles at more than 20 AI and imaging companies. The company plans to use his clinical and industry network, particularly in the U.S., to expand collaborations with healthcare institutions and industry partners.
“Neurophet possesses an impressive combination of technological innovation and strategic vision,” Tanenbaum said. He added that he plans to contribute to AI-powered imaging technologies with clinical value in real-world practice.
Neurophet’s portfolio includes Neurophet AQUA for brain MRI analysis, Neurophet SCALE PET for PET image quantitative analysis, Neurophet tES/TMS LAB for brain stimulation planning, Neurophet AQUA AD for Alzheimer’s disease treatment monitoring, and Neurophet AQUA MS for multiple sclerosis image analysis.
In February, Neurophet received U.S. Food and Drug Administration 510(k) clearance for Neurophet AQUA AD Plus. The company described the clearance as its 3rd U.S. regulatory milestone, following AQUA and SCALE PET.
“Dr. Tanenbaum is one of the world’s foremost experts at the intersection of medical imaging and artificial intelligence,” said Jake Junkil Been, co-CEO of Neurophet. Been said the appointment is expected to support the company’s clinical credibility and expansion in the U.S. and other global markets.
Company:Neurophet
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
SimonMed highlights role in large global X-ray AI study
The study analyzed 258,373 X-rays from 100 medical centers across 26 countries and evaluated the Rayvolve AI Suite across trauma, chest, measurement, and bone age use cases.
CMR-CLIP AI model interprets cardiac MRI scans with high accuracy
The model was trained on more than 13,000 cardiac MRI studies and linked moving heart images with clinical radiology reports, according to the research team.
Flywheel-AWS link creates governed imaging layer for trials
The integration combines AWS HealthImaging’s cloud-based DICOM storage with Flywheel’s imaging data orchestration tools for clinical trials, research, and AI development.
Free HelloAI training targets practical healthcare AI adoption
The company is making the HelloAI Professional track available at no cost, adding more than 20 hours of on-demand healthcare AI education.
Siemens links coronary CT planning to cath-lab PCI guidance
The system combines Syngo.CT Coronary Cockpit and Syngo PCI Connect to transfer preprocessed coronary CT angiography data into the cath lab.
AZmed gets FDA clearance for expanded AZtrauma scope
The clearance expands AZtrauma beyond fracture detection to include joint effusions and dislocations on X-rays in adults and children ages 2 years and older.
HOPPR breast imaging model converts 2D mammograms into text
The HOPPR EB 2D Mammo Narrative Model generates structured narrative output from 2D mammography images for breast imaging workflow applications.
DeepHealth secures AI clearances for neuro, prostate tools
The regulatory milestones cover Neuro Suite Brain Health and Brain Age, LumbarMR, and Prostate AI within DeepHealth’s clinical AI portfolio.
Philips SmartIQ aims to cut coronary imaging radiation dose
The coronary imaging technology adds an ultra-low-dose protocol for Philips’ Azurion image-guided therapy platform and is available in Europe and selected markets.
Azra AI, RevealDx partner on lung nodule AI
Azra AI will integrate RevealAI-Lung into its incidental findings and oncology workflow platform.
Accuro XV clearance gives Rivanna path into MSK ultrasound
Rivanna received FDA 510(k) clearance for Accuro XV, a diagnostic ultrasound system for musculoskeletal imaging. The company is also developing AI tools for bone visualization and fracture detection.
Viz.ai targets pulmonary care gaps with workflow suite
Viz.ai launched Viz Pulmonary Suite, an AI-powered platform for pulmonary embolism, COPD, and lung nodule workflows. The suite connects imaging findings, EHR data, patient summaries, guideline surfacing, and follow-up coordination.